CD8A and melanoma: Regulatory T-cells in patients with melanoma may cause CD8+ T-cells to respond weakly to melanoma antigens, creating an opportunity to use immunotherapeutic agents that allow T-cells to avoid regulatory T-cell checkpoints [24].